Jyong Biotech LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Jyong Biotech Ltd. disclosed significant challenges in its drug development program, particularly with its core candidate Botreso, facing FDA concerns regarding clinical trial data and API comparability.